Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bcg + tremelimumab
- Development stage
- Discontinued
- Lead developer
- AstraZeneca
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intravesical, Intravenous
01
Overview
BCG + tremelimumab is an investigational combination therapy consisting of the live-attenuated bacterial immunotherapy Bacillus Calmette-Guérin (BCG) and the fully human monoclonal antibody tremelimumab (formerly CP-675,206). Tremelimumab is an immune checkpoint inhibitor that targets Cytotoxic T-Lymphocyte-Associated Antigen 4 (CTLA-4), thereby enhancing T-cell activation and proliferation. BCG is a standard intravesical treatment for bladder cancer that induces a local inflammatory and immune response. This combination was evaluated in a Phase I trial (NCT00880854) by the University of Wisconsin-Madison for patients with BCG-resistant localized transitional cell carcinoma of the bladder, aiming to overcome resistance by combining local and systemic immunotherapy. The trial was ultimately withdrawn due to poor accrual.
- Brand names
- Imjudo
- Other names
- BCG + CP-675,206BCG + tremelimumabBCG + ticilimumab
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)
Beyond the preview
Go deeper on bcg + tremelimumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bcg + tremelimumab.